Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58

  • De Sanjose, Silvia|||0000-0002-5909-676X
  • Serrano, Beatriz
  • Tous, Sara|||0000-0002-5423-7092
  • Alejo, María
  • Lloveras, Belen|||0000-0001-8659-5241
  • Quiros Blasco, Beatriz|||0000-0002-6187-3732
  • Clavero, Omar|||0000-0001-9721-6382
  • Vidal, August|||0000-0001-5727-2099
  • Ferrandiz-Pulido, Carla|||0000-0003-3688-9596
  • Pavón, Miquel Ángel
  • Holzinger, Dana
  • Halec, Gordana
  • Tommasino, Massimo
  • Quint, Wim
  • Pawlita, Michael
  • Muñoz, Nubia
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
  • Alemany, Laia|||0000-0003-0945-6015
Many countries, mainly high- and upper-middle income, have implemented human papillomavirus (HPV) vaccination programs, with 47 million women receiving the full course of vaccine (three doses) in 2014. To evaluate the potential impact of HPV vaccines in the reduction of HPV-related disease, we aimed to estimate the HPV type distribution and burden of anogenital and head and neck cancers attributable to HPV types (HPVs 16/18/31/33/45/52/58/6/11) included in currently licensed HPV vaccines. In all, 18 247 formalin-fixed paraffin-embedded specimens were retrieved from 50 countries. HPV DNA detection and typing were performed with the SPF-10 PCR/DEIA/LiPA25 system. With the exception of cervical cancer, HPV DNA-positive samples were additionally subjected to HPV E6*I mRNA detection and/or p16 INK4a immunohistochemistry. For cervical cancer, estimates were based on HPV DNA, whereas for other sites, estimates were based on HPV DNA, E6*I mRNA, and p16 INK4a biomarkers. The addition of HPVs 31/33/45/52/58 to HPVs 16/18/6/11 in the nonavalent HPV vaccine could prevent almost 90% of cervical cancer cases worldwide. For other sites, the nonavalent HPV vaccine could prevent 22.8% of vulvar, 24.5% of penile, 60.7% of vaginal, 79.0% of anal cancers, 21.3% of oropharyngeal, 4.0% of oral cavity, and 2.7% of laryngeal cancer cases. Our estimations suggest a potential impact of the nonavalent HPV vaccine in reducing around 90% of cervical cancer cases and a global reduction of 50% of all the cases at HPV-related cancer sites.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Concordance of p16INK4a and E6*I mRNA among HPV-DNA-Positive Oropharyngeal, Laryngeal, and Oral Cavity Carcinomas from the ICO International Study

  • Mena, Marisa|||0000-0003-2163-892X
  • Wang, Xin
  • Tous, Sara|||0000-0002-5423-7092
  • Quiros Blasco, Beatriz|||0000-0002-6187-3732
  • Clavero, Omar|||0000-0001-9721-6382
  • Alejo, María
  • Morey, Francisca|||0000-0001-5329-9649
  • Taberna, Miren|||0000-0002-2446-186X
  • León i Vintró, Xavier|||0000-0001-6286-630X
  • Lloveras Rubio, Belén
  • Alos, Llucìa|||0000-0002-3460-0384
  • Mehanna, Hisham|||0000-0002-5544-6224
  • Quint, Wim
  • Pawlita, Michael
  • Tommasino, Massimo
  • Pavón, Miguel Angel
  • Muñoz, Nubia
  • De Sanjose, Silvia|||0000-0002-5909-676X
  • Bosch José, Francesc Xavier|||0000-0002-7172-3412
  • Alemany, Laia|||0000-0003-0945-6015
Background: Tests or test algorithms for diagnosing HPV-driven oral cavity and laryngeal head and neck carcinomas (HNC) have not been yet validated, and the differences among oral cavity and laryngeal sites have not been comprehensively evaluated. We aimed to assess the utility of a diagnostic algorithm for the detection of HPV-driven oral cavity (OCC), oropharyngeal (OPC) and laryngeal (LC) carcinomas using HPV-DNA testing followed by p16 immunohistochemistry, taking E6*I mRNA detection as the reference standard. Methods: Formalin-fixed paraffin-embedded OCC, OPC, and LC carcinomas were collected from pathology archives in 29 countries. All samples were subjected to histopathological evaluation, DNA quality control, and HPV-DNA detection. All HPV-DNA-positive samples (including 78 OCC, 257 OPC, and 51 LC out of 3680 HNC with valid HPV-DNA results) were also tested for p16 immunohistochemistry and E6*I mRNA. Three different cutoffs of nuclear and cytoplasmic staining were evaluated for p16: (a).